Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naloxegol for improving upper gastrointestinal symptoms and gastric emptying in opioid-induced constipation
2020-003687-10Phase 2Completed
- Sponsor
- UZ Leuven
- Start
- Dec 2021
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of naloxegol in opioid-induced bowel dysfunction (OIBD) and opioid-induced constipation (OIC), sponsored by UZ Leuven. Primary endpoint: GCSI-DD improvement. Started Dec 2021; status: completed.
02
Drugs
naloxegol
03
Conditions
opioid-induced bowel dysfunction (OIBD)opioid-induced constipation (OIC)
Beyond the preview
Go deeper on 2020-003687-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003687-10.